Whitehawk Therapeutics adds Vijay Iyengar to board of directors

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) appointed Vijay Iyengar, MD, to its Board of Directors effective September 9, 2026, according to an 8-K filed with the SEC. The board increased its number of authorized directors from nine to ten to create the opening Dr. Iyengar filled.¹ He was appointed as a Class III director for a term set to expire at the company's 2029 annual meeting of stockholders, subject to earlier resignation, death or removal.¹

Dr. Iyengar spent roughly nine years at Incyte Corporation (Nasdaq: INCY) in senior roles. Between May 2022 and November 2025 he led global medical affairs along with product and partnership strategy at Incyte, and from May 2016 to April 2022 he headed the company's global strategy and corporate development function.¹ Before Incyte, he held several Novartis-related positions, including President of Genoptix Medical Laboratory from April 2014 to April 2016, Vice President of the Rare Diseases Franchise at Novartis Oncology from December 2011 to March 2014, Oncology General Manager of Novartis Greece from July 2009 to November 2011, and earlier brand leadership roles at Novartis Pharmaceuticals dating back to January 2007.¹

He holds a B.S. in Biology from Stanford University and an M.D. from Harvard Medical School.¹

As a non-employee director, Dr. Iyengar will receive the standard compensation package under Whitehawk's Outside Director Compensation Policy, which includes a base annual retainer of $40,000.¹ He was also granted an initial stock option award to purchase 76,080 shares of common stock, granted September 9, 2026, vesting monthly over three years.¹ Whitehawk also entered into a standard indemnification agreement with him.¹ The company stated there are no family relationships between Dr. Iyengar and other directors or officers, and no related-party transactions under Item 404(a) of Regulation S-K.¹